The single-shot COVID-19 vaccine developed by Johnson & Johnson has been approved in the UK for use. Studies have also stated that it offers complete protection from admission to hospital and death due to COVID-19. Welcoming the UK’s approval of Johnson & Johnson COVID-19 vaccine, British Health Secretary reportedly said “This is a further boost to the UK’s hugely successful vaccination programme.” Britain has ordered 20 million doses of the vaccine. The vaccine was found to be 72 percent effective in preventing moderate to severe coronavirus infection, according to a US trial.
Britain has administered more than 62 million shots so far, mainly using the Pfizer and AstraZeneca vaccines. It has also approved the use of the Moderna vaccine. UK PM Boish Johnson took to Twitter and lauded the 'welcoming news' and said that "this will give another boost to the hugely successful vaccination programme."Johnson & Johnson on January 29 said that its COVID-19 vaccine’s single-shot efficacy is 66 per cent in preventing moderate and severe disease in a global Phase 3 trial and 85 per cent efficient against severe disease. It also said in a statement that its vaccine was 72 per cent effective against moderate and severe disease in the United States. However, the interim analysis has revealed striking different results from the ones developed by Pfizer-BioNTech and Moderna.